Calling for policy actions to increase access to long-acting antipsychotics in low-income and middle-income countries

6Citations
Citations of this article
23Readers
Mendeley users who have this article in their library.

Abstract

Schizophrenia-spectrum disorders are associated with substantial impairment and disability. Lack of treatment adherence is a major issue, especially in low- and middle-income countries (LMICs). Despite growing evidence supporting second-generation long-acting antipsychotics (LAIs) as an effective strategy to ensure continued maintenance treatment in schizophrenia, access to these technologies has been very limited in constrained-resource settings. Including second-generation LAIs in national and international essential medicines lists and evidence-based guidelines, promoting public health-oriented patent pooling and extending their availability to primary health care settings, are key actions that should urgently be implemented to increase access to long-acting technologies. Implementing these policy actions can pragmatically improve treatment adherence, ultimately tackling schizophrenia-related impairment and disability in LMICs, which can be regarded as a global health priority.

Cite

CITATION STYLE

APA

Ostuzzi, G., Gastaldon, C., Papola, D., & Barbui, C. (2022, May 11). Calling for policy actions to increase access to long-acting antipsychotics in low-income and middle-income countries. Epidemiology and Psychiatric Sciences. Cambridge University Press. https://doi.org/10.1017/S2045796022000166

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free